Quarterly ResultMay 12, 2026, 04:13 PM
Paysign Q1 Revenue +50.8% to $28.04M; Net Income +110.3% to $5.44M
AI Summary
Paysign, Inc. reported strong financial results for the first quarter of 2026, with total revenues increasing by 50.8% to $28.04 million and net income more than doubling to $5.44 million. This growth was primarily driven by a significant increase in patient affordability (pharma) revenue, which rose 81.9%, and continued expansion in plasma revenue. The company also achieved substantial margin expansion and reiterated its full-year 2026 guidance, expecting net income to nearly double over 2025.
Key Highlights
- Total revenues increased 50.8% to $28.04 million in Q1 2026 from $18.6 million in Q1 2025.
- Net income rose 110.3% to $5.44 million, or $0.09 per diluted share, compared to $2.59 million in Q1 2025.
- Pharma industry revenue grew 81.9% to $15.68 million, with 135 active patient affordability programs.
- Plasma revenue increased 24.9% to $11.75 million, with 573 active centers.
- Operating margin expanded to 23.8% from 13.4% in the prior year quarter.
- Adjusted EBITDA increased 113.4% to $10.59 million, or $0.17 per diluted share.
- Reiterated full-year 2026 revenue guidance of $106.5M $110.5M and net income of $13.0M $16.0M.
- Exited the quarter with $20.55 million in unrestricted cash and zero bank debt.